Stockscreener 앱 받기
0.5422
0.65%
-0.0081
전일 마감가:
$0.5503
열려 있는:
$0.5561
하루 거래량:
44,240
Relative Volume:
0.10
시가총액:
$11.55M
수익:
$1.89M
순이익/손실:
$-17.92M
주가수익비율:
-0.081
EPS:
-6.69
순현금흐름:
$-15.62M
1주 성능:
-15.89%
1개월 성능:
-19.80%
6개월 성능:
-57.62%
1년 성능:
-69.96%
1일 변동 폭
$0.5401
$0.5699
1주일 범위
$0.5467
$0.645
52주 변동 폭
$0.5467
$2.24
Longeveron Inc Stock (LGVN) Company Profile
명칭
Longeveron Inc
전화
305-302-7158
주소
1951 NW 7TH AVENUE, MIAMI
LGVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.5413 | 11.74M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.25 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.62 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.66 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.11 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.33 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
Longeveron Inc 주식(LGVN)의 최신 뉴스
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Prepare Yourself for Liftoff: Longeveron Inc (LGVN) - Setenews
Update Recap: Can MCK stock sustain institutional flowsWatch List & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Longeveron granted Canadian patent covering laromestrocel administration - MSN
Longeveron executives to speak at CVCT Forum on cell therapy trials - Investing.com Nigeria
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - The Manila Times
Longeveron (NASDAQ: LGVN) CSO, CMO to Join CVCT Forum Panels on Cell Therapy Trials - Stock Titan
Can Longeveron Inc. stock continue upward trendWeekly Trend Recap & Fast Entry Momentum Alerts - Newser
Longeveron (LGVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Longeveron receives Canadian patent for stem cell therapy By Investing.com - Investing.com Nigeria
Perhaps timely catching Longeveron Inc (LGVN) would be a good idea - Setenews
Longeveron receives Canadian patent for stem cell therapy - Investing.com
Longeveron granted Canadian patent for method of using stem cells to treat non-ischemic dilated cardiomyopathy - MarketScreener
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - The Manila Times
Longeveron (NASDAQ: LGVN) gets Canada patent on LOMECEL-B for frailty and NIDCM - Stock Titan
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial By Investing.com - Investing.com South Africa
Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025 - TipRanks
Longeveron (NASDAQ: LGVN) sees MRI inflammation drop in 13 of 14 brain regions at week 39 - Stock Titan
Longeveron (NASDAQ:LGVN) Shares Up 3% – Should You Buy? - Defense World
Longeveron announces board member resignation - MSN
Is Longeveron Inc. stock a buy in volatile marketsJuly 2025 Price Swings & Safe Swing Trade Setups - moha.gov.vn
Longeveron Inc. (LGVN) Jumps 6% in Pre-market: What’s Driving the Move? - Stocks Telegraph
Will Longeveron Inc. stock attract more institutional investorsJuly 2025 Selloffs & Entry Point Confirmation Signals - BỘ NỘI VỤ
Longeveron Inc. (LGVN) 5.03% in After-hours: What’s Driving the Move? - Stocks Telegraph
Take off with Longeveron Inc (LGVN): Get ready for trading - Setenews
What data driven models say about Longeveron Inc.’s futureJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Longeveron Inc. (LGVN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Longeveron to present Alzheimer's treatment data at CTAD 2025 By Investing.com - Investing.com Nigeria
Longeveron to present Alzheimer’s treatment data at CTAD 2025 By Investing.com - Investing.com Australia
Will Longeveron Inc. stock remain a Wall Street favorite2025 Dividend Review & Community Shared Stock Ideas - newser.com
Longeveron to present Alzheimer’s treatment data at CTAD 2025 - Investing.com
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron (NASDAQ: LGVN) Presenting Laromestrocel CLEAR MIND Data at CTAD 2025 - Stock Titan
Why analysts upgrade Longeveron Inc. stock2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Visualizing Longeveron Inc. stock with heatmapsJuly 2025 Momentum & Short-Term Swing Trade Alerts - newser.com
What drives Longeveron Inc stock priceHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
What dividend safety score for Longeveron Inc. stockWeekly Risk Report & Entry Point Confirmation Signals - newser.com
How Longeveron Inc. stock compares to growth peersJuly 2025 Big Picture & Expert Verified Movement Alerts - Fundação Cultural do Pará
Is Longeveron Inc. stock recession proof2025 Volume Leaders & High Accuracy Investment Signals - Fundação Cultural do Pará
Longeveron Faces Nasdaq Delisting Notice for Stock Price - MSN
Will Longeveron Inc. stock continue dividend increasesPortfolio Growth Summary & Weekly High Return Stock Forecasts - newser.com
Longeveron secures patent for stem cell therapy targeting aging frailty By Investing.com - Investing.com Nigeria
Longeveron announces resignations of two board members By Investing.com - Investing.com Australia
Longeveron Inc (LGVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Longeveron Inc 주식 (LGVN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.42%
0.32%
자본화:
|
볼륨(24시간):